A
AARD
Aardvark Therapeutics, Inc. Common Stock
$3.88
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Aardvark Therapeutics, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$3.21
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.71
Nov 12
Posts
No posts about AARD yet.
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics is a small US drug developer that has no approved products and no sales yet. It spends investor money on clinical trials for experimental medicines, with a focus on treatments for appetite and metabolic conditions. The company only makes money if a drug wins approval and reaches the market, or if it signs a deal with a larger drug maker.